Does Kaiser Permanente Cover Eliquis?

Kaiser Permanente Formulary Placement for Eliquis

Kaiser Permanente includes Eliquis (apixaban) on its drug formularies across most regions, reflecting its position as one of the two most-prescribed direct oral anticoagulants (DOACs) in the United States. The drug earned FDA approval in 2012 for stroke prevention in non-valvular atrial fibrillation and subsequently for treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1].

Regional Variation in Tier Placement

Kaiser operates as a regional health system with separate formulary committees in California (Northern and Southern), Colorado, Georgia, Hawaii, the Mid-Atlantic states, the Northwest, and Washington. Each region maintains its own pharmacy and therapeutics committee, which means tier placement can differ. In Northern California, Eliquis has historically appeared on Tier 3 as a preferred brand. In the Northwest region, it may appear on Tier 4 with a higher cost-sharing obligation.

How Kaiser's Closed Pharmacy Model Affects Access

Unlike open-network insurers, Kaiser members fill prescriptions through Kaiser's own pharmacies (mail-order or in-person at Kaiser facilities). This closed system gives Kaiser greater negotiating use with manufacturers. Bristol-Myers Squibb and Pfizer (co-marketers of Eliquis) have maintained agreements with Kaiser that keep apixaban accessible, though the exact rebate structure remains proprietary [2].

Formulary Updates and Annual Changes

Kaiser publishes formulary updates quarterly. A drug's tier can shift during open enrollment periods or mid-year if the P&T committee votes to reclassify it. Members should verify current placement through the Kaiser Permanente drug formulary search tool specific to their region before assuming coverage terms from a prior year still apply.

Eliquis Copay Costs at Kaiser Permanente

The out-of-pocket cost for Eliquis at Kaiser depends on three variables: the member's specific plan design, their region, and whether they have reached their annual deductible. For a standard Kaiser commercial HMO, brand-name copays on Tier 3 typically fall between $30 and $60 per 30-day supply. Members on high-deductible health plans (HDHPs) may pay the full negotiated price until meeting their deductible, which can exceed $500 per month for Eliquis at retail pricing.

Medicare Advantage Plans

Kaiser's Medicare Advantage plans cover Eliquis under Part D. Members in the Initial Coverage Phase (after meeting any applicable deductible) typically pay 25% coinsurance or a flat copay of $42 to $95 depending on tier. Once members enter the Coverage Gap (formerly the "donut hole"), they pay no more than 25% of the plan's negotiated price for brand-name drugs under the Inflation Reduction Act provisions that took effect in 2025 [3].

Reducing Your Out-of-Pocket Cost

The Bristol-Myers Squibb/Pfizer Eliquis Savings Card covers copays up to $6,400 per year for commercially insured patients, potentially reducing cost to $0 per fill. This card is not valid for Kaiser Medicare Advantage or Medicaid members. Kaiser members should confirm with their pharmacy that the savings card can be applied at Kaiser-owned pharmacies, as acceptance policies vary by region.

Prior Authorization and Step Therapy Requirements

Kaiser Permanente generally does not impose prior authorization for Eliquis when prescribed for its FDA-approved indications: stroke prevention in non-valvular atrial fibrillation (NVAF), treatment of DVT and PE, and prophylaxis of recurrent DVT and PE. The 2023 AHA/ACC/ACCP/HRS guideline for management of atrial fibrillation recommends DOACs over warfarin for most patients with AFib, reinforcing Eliquis as a first-line therapy rather than a step-therapy candidate [4].

When Prior Authorization May Apply

Some Kaiser regions require prior authorization for off-label uses of Eliquis, such as:

• Cancer-associated thrombosis (where low-molecular-weight heparin or edoxaban may be preferred per ASCO guidelines)
• Post-orthopedic surgery prophylaxis beyond standard durations
• Left ventricular thrombus management
• Antiphospholipid syndrome (where warfarin remains preferred per ACR guidelines)

What Your Prescriber Needs to Document

If prior authorization is triggered, the prescribing physician must document the ICD-10 diagnosis code (I48.x for AFib, I26.x for PE, I82.x for DVT), confirm no contraindications, and indicate that dosing follows FDA labeling. Kaiser's internal clinical pharmacists review PA requests, and turnaround is typically 24 to 72 hours.

Clinical Evidence Supporting Eliquis Coverage

Kaiser's formulary inclusion of Eliquis reflects the drug's strong efficacy and safety data. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared to warfarin (HR 0.79, 95% CI 0.66-0.95, P=0.01), while also reducing major bleeding by 31% (HR 0.69, 95% CI 0.60-0.80, P<0.001) and all-cause mortality by 11% (HR 0.89, 95% CI 0.80-0.99, P=0.047) [5].

Comparative Safety Data

The ARISTOTLE results positioned apixaban favorably against both warfarin and other DOACs. A 2022 network meta-analysis published in the BMJ comparing all four approved DOACs found that apixaban had the lowest rate of major bleeding among DOACs while maintaining non-inferior efficacy for stroke prevention [6]. This safety profile likely contributed to Kaiser's decision to maintain Eliquis at a preferred tier rather than restricting it behind step therapy.

Real-World Evidence From Kaiser's Own System

Kaiser Permanente's integrated health records have generated real-world evidence on DOAC outcomes. A 2021 study from Kaiser Permanente Northern California (N=64,661) published in JAMA Network Open found that apixaban was associated with lower rates of major bleeding compared to rivaroxaban (HR 0.63, 95% CI 0.56-0.71) in patients with atrial fibrillation, consistent with randomized trial data [7].

Dr. Alan Go, a research scientist at Kaiser Permanente Northern California Division of Research, noted: "Our findings from a large, diverse, community-based population reinforce the favorable safety profile of apixaban relative to rivaroxaban for patients with atrial fibrillation managed in routine clinical practice" [7].

Eliquis Dosing and Quantity Limits at Kaiser

Kaiser's standard dispensing quantity for Eliquis is 60 tablets per 30-day supply, corresponding to the standard dose of 5 mg twice daily. For patients who qualify for the reduced dose of 2.5 mg twice daily (age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher, with at least two of three criteria met), the same 60-tablet quantity applies [8].

90-Day Mail Order

Kaiser offers 90-day supplies through its mail-order pharmacy service, which can reduce per-unit copay costs. For members on plans with flat copays, a 90-day fill often costs 2.5 times the 30-day copay rather than 3 times, yielding a modest savings of one-sixth per quarter.

Quantity Limit Exceptions

Requests exceeding 60 tablets per 30 days require a quantity limit exception, which is rarely approved since no FDA-approved indication calls for more than 10 mg total daily dose. Post-surgical VTE prophylaxis at 2.5 mg twice daily also stays within the 60-tablet allotment.

How to Verify Your Specific Kaiser Eliquis Coverage

Because Kaiser operates regionally, the most reliable method for confirming coverage is checking your specific plan's formulary.

Step-by-Step Verification

1. Log into kp.org and manage to "Pharmacy" then "Drug Formulary"
2. Search for "apixaban" or "Eliquis"
3. Note the tier, any restrictions listed (PA, ST, QL), and your plan's copay for that tier
4. If the drug shows as non-formulary or restricted, call the Kaiser pharmacy advice line for your region

If Coverage Is Denied

Members who receive a coverage denial can file an expedited appeal through Kaiser's internal grievance process. Under California law (and similar statutes in other Kaiser states), health plans must respond to expedited formulary exception requests within 24 hours when medically necessary. The prescribing physician must submit a letter of medical necessity explaining why Eliquis is required over formulary alternatives.

Comparing Eliquis to Other Anticoagulants on Kaiser's Formulary

Kaiser formularies typically include multiple anticoagulant options. Understanding the alternatives helps contextualize Eliquis's coverage position.

Warfarin (Generic)

Warfarin sits on Tier 1 (generic) at Kaiser, with copays of $5 to $15 per month. It requires regular INR monitoring (typically every 2 to 4 weeks), has numerous food and drug interactions, and carries a higher intracranial hemorrhage risk than DOACs. The 2023 AHA/ACC guideline reserves warfarin for patients with mechanical heart valves, moderate-to-severe mitral stenosis, or antiphospholipid syndrome [4].

Rivaroxaban (Xarelto)

Rivaroxaban appears on a similar tier to Eliquis at most Kaiser regions. It offers once-daily dosing for AFib (20 mg with evening meal) but showed higher GI bleeding rates than apixaban in both the ROCKET AF trial and real-world Kaiser data [7]. Some patients prefer its once-daily convenience despite the safety trade-off.

Edoxaban (Savaysa)

Edoxaban is less commonly prescribed and may appear on a higher tier or require prior authorization at Kaiser. The ENGAGE AF-TIMI 48 trial demonstrated non-inferiority to warfarin, but the drug carries an FDA boxed warning against use in patients with CrCl greater than 95 mL/min due to reduced efficacy in that population [9].

Special Populations and Coverage Considerations

Patients With Renal Impairment

Kaiser covers Eliquis for patients with CrCl 25 mL/min or above without additional restrictions. For patients on hemodialysis, the FDA approved apixaban 5 mg twice daily (or 2.5 mg twice daily if other dose-reduction criteria are met) based on pharmacokinetic modeling, though clinical outcomes data in this population remain limited [10]. Kaiser may require documentation of nephrologist consultation for dialysis patients.

Patients Transitioning From Warfarin

Kaiser pharmacists support warfarin-to-Eliquis transitions without requiring new prior authorization. The standard protocol is to discontinue warfarin and start apixaban when INR falls below 2.0. No bridging with injectable anticoagulants is needed for this transition in stable patients [8].

The American College of Chest Physicians (ACCP) 2021 guideline on VTE management states: "For patients with VTE who are transitioned from a vitamin K antagonist to a DOAC, we suggest initiating the DOAC when the INR is below the therapeutic range" [11].

Kaiser Permanente Eliquis Coverage by Plan Type

Coverage specifics vary by plan category. Here is a general framework based on publicly available Kaiser formulary documents:

Commercial HMO (employer-sponsored): Covered at Tier 3 with $30-$60 copay per 30-day supply. No prior authorization for FDA-approved indications. Manufacturer copay card eligible.

Individual/Family (ACA Marketplace): Covered at Tier 3 or Tier 4 depending on metal level. Silver and Gold plans typically have lower copays ($35-$55) than Bronze plans ($60-$95). Deductible may apply on Bronze plans.

Medicare Advantage (Part D): Covered under Part D formulary. Members pay 25% coinsurance after deductible in Initial Coverage Phase. $2,000 annual out-of-pocket cap on Part D drugs applies starting 2025 per the Inflation Reduction Act [3].

Medi-Cal (California Medicaid managed by Kaiser): Eliquis is covered with minimal or no cost-sharing for qualifying members. Prior authorization requirements follow state Medi-Cal guidelines.

What to Do If Kaiser Denies Eliquis Coverage

Denials are uncommon for standard indications but can occur for off-label use, dose exceptions, or administrative errors.

Appeal Process

File a formal appeal within 60 days of denial. Include the prescriber's letter of medical necessity, relevant clinical trial citations (ARISTOTLE for AFib, AMPLIFY for VTE), and documentation of why alternatives are inappropriate for your clinical situation. Kaiser must respond within 30 days for standard appeals or 72 hours for expedited appeals involving urgent medical need.

External Review

If the internal appeal is denied, members in all Kaiser states have the right to an Independent Medical Review (IMR) through their state's Department of Managed Health Care or Department of Insurance. In California, the DMHC processes IMR requests within 30 days, and the decision is binding on Kaiser [12].

Members who exhaust pharmacy benefit options should ask their prescribing physician whether samples are available at Kaiser facilities during the appeal period to avoid gaps in anticoagulation therapy, which carry stroke risk for AFib patients.